• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Cytogen submits U.S. data in Europe

Article

Cytogen of Princeton, NJ, appeared before the Committee for ProprietaryMedicinal Products of the European Community this month with anapplication to register OncoScint CR103, a colorectal cancer monoclonalantibody imaging agent. The CPMP last week

Cytogen of Princeton, NJ, appeared before the Committee for ProprietaryMedicinal Products of the European Community this month with anapplication to register OncoScint CR103, a colorectal cancer monoclonalantibody imaging agent. The CPMP last week requested the companyto provide written confirmation of its oral presentations, saidCheryl Shipley Coyle, Cytogen director of marketing and corporatecommunications.

EuroCetus, Cytogen's European marketing partner (SCAN 1/17/90),is handling the regulatory process for the U.S. company. All datafor the application were obtained through U.S. clinical trials,Coyle said. She could not confirm, however, whether this is thefirst time a European monoclonal antibody application has beenmade without supporting European data.

Although the CPMP has yet not handed down a decision, the factthat it did not reject the application out of hand because ofthe lack of European data is a hopeful sign for U.S. monoclonalantibody developers.

Centocor's Myoscint cardiac agent is the only monoclonal antibodyimaging agent to have received CPMP endorsement (SCAN 6/15/89).Myoscint has also received national approvals, which are requiredbefore marketing can take place in individual European countries.No monoclonal antibody imaging agents have been approved for marketin the U.S.

Cytogen expected a rigorous process for the OncoScint application.

"As this is going to be the first monoclonal agent forcancer, they (the CPMP) are dotting their i's and crossing theirt's," Coyle said.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.